ADDITIONAL CONDITIONS THAT MAY BE A FOCUS OF CLINICAL ATTENTION

V15.81 Noncompliance With Treatment
V65.2 Malingering
V71.01 Adult Antisocial Behavior
V71.02 Child or Adolescent Antisocial Behavior
V62.89 Borderline Intellectual Functioning

*Note: This is coded on Axis II.*

780.9 Age-Related Cognitive Decline
V62.82 Bereavement
V62.3 Academic Problem
V62.2 Occupational Problem
313.82 Identity Problem
V62.89 Religious or Spiritual Problem
V62.4 Acculturation Problem
V62.89 Phase of Life Problem

ADDITIONAL CODES

300.9 Unspecified Mental Disorder (nonpsychotic)
V71.09 No Diagnosis or Condition on Axis I
799.9 Diagnosis or Condition Deferred on Axis I
V71.09 No Diagnosis on Axis II
799.9 Diagnosis Deferred on Axis II

MULTIAXIAL SYSTEM

Axis I Clinical Disorders
Axis II Other Conditions That May Be a Focus of Clinical Attention
Axis III Personality Disorders
Axis IV Mental Retardation
Axis V General Medical Conditions
Axis VI Psychosocial and Environmental Problems
Axis VII Global Assessment of Functioning

FOR FIRST-LINE THERAPY IN DEPRESSION

CHOOSE ZOLOFT® (sertraline HCl)

Please see last pages for full prescribing information.
DISORDERS USUALLY FIRST DIAGNOSED IN INFANCY, CHILDHOOD, OR ADOLESCENCE

Mental Retardation

Note: These are coded on Axis II.
317    Mild Mental Retardation
318.0  Moderate Mental Retardation
318.1  Severe Mental Retardation
318.2  Profound Mental Retardation
319    Mental Retardation, Severity Unspecified

Learning Disorders
315.00 Reading Disorder
315.1  Mathematics Disorder
315.2  Disorder of Written Expression
315.9  Learning Disorder NOS

Motor Skills Disorder
315.4  Developmental Coordination Disorder

Communication Disorders
315.31 Expressive Language Disorder
315.31 Mixed Receptive-Expressive Language Disorder
315.39 Phonological Disorder
307.0  Stuttering
307.9  Communication Disorder NOS

Pervasive Developmental Disorders
299.00 Autistic Disorder
299.80 Rett's Disorder
299.10 Childhood Disintegrative Disorder
299.80 Asperger's Disorder
299.80 Pervasive Developmental Disorder NOS
Attention-Deficit and Disruptive Behavior Disorders

314.xx Attention-Deficit/Hyperactivity Disorder
  .01 Combined Type
  .00 Predominantly Inattentive Type
  .01 Predominantly Hyperactive-Impulsive Type
314.9 Attention-Deficit/Hyperactivity Disorder NOS
312.8 Conduct Disorder
  Specify type: Childhood-Onset Type/Adolescent-Onset Type
313.81 Oppositional Defiant Disorder
312.9 Disruptive Behavior Disorder NOS

Feeding and Eating Disorders of Infancy or Early Childhood

307.52 Pica
307.53 Rumination Disorder
307.59 Feeding Disorder of Infancy or Early Childhood

Tic Disorders

307.23 Tourette's Disorder
307.22 Chronic Motor or Vocal Tic Disorder
307.21 Transient Tic Disorder
  Specify if: Single Episode/Recurrent
307.20 Tic Disorder NOS

Elimination Disorders

___ Encopresis
787.6 With Constipation and Overflow Incontinence
307.7 Without Constipation and Overflow Incontinence
307.6 Enuresis (Not Due to a General Medical Condition)
  Specify type: Nocturnal Only/Diurnal Only/Nocturnal and Diurnal

Other Disorders of Infancy, Childhood, or Adolescence

309.21 Separation Anxiety Disorder
  Specify if: Early Onset
313.23 Selective Mutism
313.89 Reactive Attachment Disorder of Infancy or Early Childhood
  Specify type: Inhibited Type/Disinhibited Type
307.3 Stereotypic Movement Disorder
  Specify if: With Self-Injurious Behavior
313.9 Disorder of Infancy, Childhood, or Adolescence NOS

Delirium

293.0 Delirium Due to...
  [Indicate the General Medical Condition]
  ___ Substance Intoxication Delirium (refer to Substance-Related Disorders for substance-specific codes)
  ___ Substance Withdrawal Delirium (refer to Substance-Related Disorders for substance-specific codes)
  ___ Delirium Due to Multiple Etiologies (code each of the specific etiologies)
780.09 Delirium NOS

Dementia

290.xx Dementia of the Alzheimer's Type, With Early Onset (also code 331.0 Alzheimer's disease on Axis III)
  .10 Uncomplicated
  .11 With Delirium
  .12 With Delusions
  .13 With Depressed Mood
  Specify if: With Behavioral Disturbance

DELIRIUM, DEMENTIA, AND AMNESTIC AND OTHER COGNITIVE DISORDERS
Substance-Induced Persisting Dementia
(refer to Substance-Related Disorders for substance-specific codes)

Dementia Due to Multiple Etiologies (code each of the specific etiologies)

294.8 Dementia NOS

Amnestic Disorders
294.0 Amnestic Disorder Due to ... [Indicate the General Medical Condition]
Specify if: Transient/Chronic

Substance-Induced Persisting Amnestic Disorder (refer to Substance-Related Disorders for substance-specific codes)

294.8 Amnestic Disorder NOS

Other Cognitive Disorders
294.9 Cognitive Disorder NOS

MENTAL DISORDERS DUE TO A GENERAL MEDICAL CONDITION NOT ELSEWHERE CLASSIFIED

293.89 Catatonic Disorder Due to ... [Indicate the General Medical Condition]

310.1 Personality Change Due to ... [Indicate the General Medical Condition]
Specify type: Labile Type/Disinhibited Type/Aggressive Type/Apathetic Type/Paranoid Type/Other Type/Combined Type/Unspecified Type

293.9 Mental Disorder NOS Due to ... [Indicate the General Medical Condition]
### Substance-Related Disorders

The following specifiers may be applied to Substance Dependence:
- With Physiological Dependence/Without Physiological Dependence
- Early Full Remission/Early Partial Remission
- Sustained Full Remission/Sustained Partial Remission
- On Agonist Therapy/In a Controlled Environment

The following specifiers apply to Substance-Induced Disorders as noted:
- With Onset During Intoxication
- With Onset During Withdrawal

### Alcohol-Related Disorders

**Alcohol Use Disorders**
- Alcohol Dependence
  - 303.90
- Alcohol Abuse
  - 305.00

**Alcohol-Induced Disorders**
- Alcohol Intoxication
  - 303.00
- Alcohol Withdrawal
  - 291.8
  - Specify if: With Perceptual Disturbances
- Alcohol Intoxication Delirium
  - 291.0
- Alcohol Withdrawal Delirium
  - 291.0
- Alcohol-Induced Persisting Dementia
  - 291.2
- Alcohol-Induced Persisting Amnestic Disorder
  - 291.1
- Alcohol-Induced Psychotic Disorder
  - 291.x
  - Specify if: With Delusions
  - 291.5
  - With Hallucinations
  - 291.3
- Alcohol-Induced Mood Disorder
  - 291.8
  - Specify if: With Delusions
  - 291.8
  - With Hallucinations
  - 291.8
- Alcohol-Induced Anxiety Disorder
  - 291.8
- Alcohol-Induced Sexual Dysfunction
  - 291.8
- Alcohol-Induced Sleep Disorder
  - 291.8
- Alcohol-Related Disorder NOS
  - 291.9

### Amphetamine (or Amphetamine-Like)-Related Disorders

**Amphetamine Use Disorders**
- Amphetamine Dependence
  - 304.40
- Amphetamine Abuse
  - 305.70

**Amphetamine-Induced Disorders**
- Amphetamine Intoxication
  - 292.89
  - Specify if: With Perceptual Disturbances
- Amphetamine Withdrawal
  - 292.0
- Amphetamine Intoxication Delirium
  - 292.81
- Amphetamine-Induced Psychotic Disorder
  - 292.x
  - Specify if: With Delusions
  - 292.81
  - With Hallucinations
  - 292.81
- Amphetamine-Induced Mood Disorder
  - 292.89
- Amphetamine-Induced Anxiety Disorder
  - 292.89
- Amphetamine-Induced Sexual Dysfunction
  - 292.89
- Amphetamine-Induced Sleep Disorder
  - 292.89
- Amphetamine-Related Disorder NOS
  - 292.9

### Caffeine-Related Disorders

**Caffeine-Induced Disorders**
- Caffeine Intoxication
  - 305.90
- Caffeine-Induced Anxiety Disorder
  - 292.9
- Caffeine-Induced Sleep Disorder
  - 292.9
- Caffeine-Related Disorder NOS
  - 292.9

### Cannabis-Related Disorders

**Cannabis Use Disorders**
- Cannabis Dependence
  - 304.30
- Cannabis Abuse
  - 305.20

---

**Please see last pages for full prescribing information.**
Cannabis-Induced Disorders
292.89 Cannabis Intoxication
   Specify if: With Perceptual Disturbances
292.81 Cannabis Intoxication Delirium
292.xx Cannabis-Induced Psychotic Disorder
   .11 With Delusions
   .12 With Hallucinations
292.89 Cannabis-Induced Anxiety Disorder
292.9 Cannabis-Related Disorder NOS

Cocaine-Related Disorders
Cocaine Use Disorders
304.20 Cocaine Dependence
305.60 Cocaine Abuse

Cocaine-Induced Disorders
292.89 Cocaine Intoxication
   Specify if: With Perceptual Disturbances
292.0 Cocaine Withdrawal
292.81 Cocaine Intoxication Delirium
292.xx Cocaine-Induced Psychotic Disorder
   .11 With Delusions
   .12 With Hallucinations
292.84 Cocaine-Induced Mood Disorder
292.89 Cocaine-Induced Anxiety Disorder
292.9 Cocaine-Related Disorder NOS

Hallucinogen-Related Disorders
Hallucinogen Use Disorders
304.50 Hallucinogen Dependence
305.30 Hallucinogen Abuse

Hallucinogen-Induced Disorders
292.89 Hallucinogen Intoxication
292.89 Hallucinogen Persisting Perception Disorder (Flashbacks)

292.81 Hallucinogen Intoxication Delirium
292.xx Hallucinogen-Induced Psychotic Disorder
   .11 With Delusions
   .12 With Hallucinations
292.84 Hallucinogen-Induced Mood Disorder
292.89 Hallucinogen-Induced Anxiety Disorder
292.9 Hallucinogen-Related Disorder NOS

Inhalant-Related Disorders
Inhalant Use Disorders
304.60 Inhalant Dependence
305.90 Inhalant Abuse

Inhalant-Induced Disorders
292.89 Inhalant Intoxication
292.81 Inhalant Intoxication Delirium
292.82 Inhalant-Induced Persisting Dementia
292.xx Inhalant-Induced Psychotic Disorder
   .11 With Delusions
   .12 With Hallucinations
292.84 Inhalant-Induced Mood Disorder
292.89 Inhalant-Induced Anxiety Disorder
292.9 Inhalant-Related Disorder NOS

Nicotine-Related Disorders
Nicotine Use Disorder
305.10 Nicotine Dependence

Nicotine-Induced Disorder
292.0 Nicotine Withdrawal
292.9 Nicotine-Related Disorder NOS

Opioid-Related Disorders
Opioid Use Disorders
304.00 Opioid Dependence
305.50 Opioid Abuse

CHOOSE ZOLOFT® (sertraline HCl)
FOR FIRST-LINE THERAPY IN DEPRESSION

Please see last pages for full prescribing information.
**Opioid-Induced Disorders**
- 292.89 Opioid Intoxication
  - Specify if: With Perceptual Disturbances
- 292.0 Opioid Withdrawal
- 292.81 Opioid Intoxication Delirium
- 292.xx Opioid-Induced Psychotic Disorder
  - .11 With Delusions
  - .12 With Hallucinations
- 292.84 Opioid-Induced Mood Disorder
- 292.89 Opioid-Induced Sexual Dysfunction
- 292.89 Opioid-Induced Sleep Disorder
- 292.9 Opioid-Related Disorder NOS

**Phencyclidine (or Phencyclidine-Like)—Related Disorders**

**Phencyclidine Use Disorders**
- 304.90 Phencyclidine Dependence
- 305.90 Phencyclidine Abuse

**Phencyclidine-Induced Disorders**
- 292.89 Phencyclidine Intoxication
  - Specify if: With Perceptual Disturbances
- 292.81 Phencyclidine Intoxication Delirium
- 292.xx Phencyclidine-Induced Psychotic Disorder
  - .11 With Delusions
  - .12 With Hallucinations
- 292.84 Phencyclidine-Induced Mood Disorder
- 292.89 Phencyclidine-Induced Anxiety Disorder
- 292.9 Phencyclidine-Related Disorder NOS

**Sedative-, Hypnotic-, or Anxiolytic-Related Disorders**

**Sedative, Hypnotic, or Anxiolytic Use Disorders**
- 304.10 Sedative, Hypnotic, or Anxiolytic Dependence
- 305.40 Sedative, Hypnotic, or Anxiolytic Abuse

**Sedative-, Hypnotic-, or Anxiolytic-Induced Disorders**
- 292.89 Sedative, Hypnotic, or Anxiolytic Intoxication
- 292.0 Sedative, Hypnotic, or Anxiolytic Withdrawal
  - Specify if: With Perceptual Disturbances
- 292.81 Sedative, Hypnotic, or Anxiolytic Intoxication Delirium
- 292.81 Sedative, Hypnotic, or Anxiolytic Withdrawal Delirium
- 292.82 Sedative-, Hypnotic-, or Anxiolytic-Induced Persisting Dementia
- 292.83 Sedative-, Hypnotic-, or Anxiolytic-Induced Persisting Amnestic Disorder
- 292.xx Sedative-, Hypnotic-, or Anxiolytic-Induced Psychotic Disorder
  - .11 With Delusions
  - .12 With Hallucinations
- 292.84 Sedative-, Hypnotic-, or Anxiolytic-Induced Mood Disorder
- 292.89 Sedative-, Hypnotic-, or Anxiolytic-Induced Anxiety Disorder
- 292.89 Sedative-, Hypnotic-, or Anxiolytic-Induced Sexual Dysfunction
- 292.89 Sedative-, Hypnotic-, or Anxiolytic-Induced Sleep Disorder
- 292.9 Sedative-, Hypnotic-, or Anxiolytic-Related Disorder NOS

**Polysubstance-Related Disorder**
- 304.80 Polysubstance Dependence

**Other (or Unknown) Substance-Related Disorders**

**Other (or Unknown) Substance Use Disorders**
- 304.90 Other (or Unknown) Substance Dependence
- 305.90 Other (or Unknown) Substance Abuse
Other (or Unknown) Substance-Induced Disorders

292.89 Other (or Unknown) Substance Intoxication
   Specify if: With Perceptual Disturbances
292.0 Other (or Unknown) Substance Withdrawal
   Specify if: With Perceptual Disturbances
292.81 Other (or Unknown) Substance-Induced Delirium
292.82 Other (or Unknown) Substance-Induced Persisting Dementia
292.83 Other (or Unknown) Substance-Induced Persisting Amnestic Disorder
292.xx Other (or Unknown) Substance-Induced Psychotic Disorder
   .11 With Delusions
   .12 With Hallucinations
292.84 Other (or Unknown) Substance-Induced Mood Disorder
292.89 Other (or Unknown) Substance-Induced Anxiety Disorder
292.89 Other (or Unknown) Substance-Induced Sexual Dysfunction
292.89 Other (or Unknown) Substance-Induced Sleep Disorder
292.9 Other (or Unknown) Substance-Related Disorder NOS

SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS

295.xx Schizophrenia

The following Classification of Longitudinal Course applies to all subtypes of Schizophrenia:
   Episodic With Interepisode Residual Symptoms
      (specify if: With Prominent Negative Symptoms)/Episodic With No Interepisode Residual Symptoms

Continuous
   (specify if: With Prominent Negative Symptoms)
Single Episode In Partial Remission
   (specify if: With Prominent Negative Symptoms)/Single Episode In Full Remission
Other or Unspecified Pattern
   .30 Paranoid Type
   .10 Disorganized Type
   .20 Catatonic Type
   .90 Undifferentiated Type
   .60 Residual Type
295.40 Schizophreniform Disorder
   Specify if: Without Good Prognostic Features/With Good Prognostic Features
295.70 Schizoaffective Disorder
   Specify type: Bipolar Type/Depressive Type
297.1 Delusional Disorder
   Specify type: Erotomanic Type/Grandiose Type/Jealous Type/Persecutory Type/
   Somatic Type/Mixed Type/Unspecified Type
298.8 Brief Psychotic Disorder
   Specify if: With Marked Stressor(s)/Without Marked Stressor(s)/With Postpartum Onset
297.3 Shared Psychotic Disorder
293.xx Psychotic Disorder Due to ... (Indicate the General Medical Condition)
   .81 With Delusions
   .82 With Hallucinations
   Substance-Induced Psychotic Disorder
      (refer to Substance-Related Disorders for substance-specific codes)
      Specify if: With Onset During Intoxication/With Onset During Withdrawal
298.9 Psychotic Disorder NOS

CHOOSE ZOLOFT® (sertraline HCl)

FOR FIRST-LINE THERAPY IN DEPRESSION
**MOOD DISORDERS**

Code current state of Major Depressive Disorder or Bipolar I Disorder in fifth digit:

1 = Mild
2 = Moderate
3 = Severe Without Psychotic Features
4 = Severe With Psychotic Features

*Specify: Mood-Congruent Psychotic Features/Mood-Incongruent Psychotic Features

5 = In Partial Remission
6 = In Full Remission
0 = Unspecified

The following specifiers apply (for current or most recent episode) to Mood Disorders as noted:

*Severity/Psychotic/Remission Specifiers/*Chronic/
*With Catatonic Features/*With Melancholic Features/
*With Atypical Features/*With Postpartum Onset

DEPRESSIVE DISORDERS

296.xx Major Depressive Disorder,
.2x Single Episode
.3x Recurrent
300.4 Dysthymic Disorder

Specify if: Early Onset/Late Onset
Specify: With Atypical Features

311 Depressive Disorder NOS

BIPOLAR DISORDERS

296.xx Bipolar I Disorder,
.0x Single Manic Episode
.40 Most Recent Episode Hypomanic
.4x Most Recent Episode Manic
.6x Most Recent Episode Mixed
.5x Most Recent Episode Depressed
.7 Most Recent Episode Unspecified

296.89 Bipolar II Disorder

Specify (current or most recent episode): Hypomanic/Depressed

301.13 Cyclothymic Disorder

296.80 Bipolar Disorder NOS

293.83 Mood Disorder Due to .../[Indicate the General Medical Condition]

*Specify type: With Depressive Features/With Major Depressive-Like Episode/With Manic Features/With Mixed Features

Substance-Induced Mood Disorder (refer to Substance-Related Disorders for substance-specific codes)

Specify type: With Depressive Features/With Manic Features/With Mixed Features

Specify if: With Onset During Intoxication/With Onset During Withdrawal

296.90 Mood Disorder NOS

ANXIETY DISORDERS

300.01 Panic Disorder Without Agoraphobia
300.21 Panic Disorder With Agoraphobia
300.22 Agoraphobia Without History of Panic Disorder

300.29 Specific Phobia

Specify type: Animal Type/Natural Environment Type/Blood-Injection-Injury Type/Situational Type/Other Type

**CHOOSE ZOLOFT** (sertraline HCl)

Please see last pages for full prescribing information.

**FOR FIRST-LINE THERAPY IN DEPRESSION**
300.23 Social Phobia
   Specify if: Generalized
300.3 Obsessive-Compulsive Disorder
   Specify if: With Poor Insight
309.81 Posttraumatic Stress Disorder
   Specify if: Acute/Chronic
   Specify if: With Delayed Onset
308.3 Acute Stress Disorder
300.02 Generalized Anxiety Disorder
293.89 Anxiety Disorder Due to ... [Indicate the General Medical Condition]
   Specify if: With Generalized Anxiety/With Panic Attacks/With Obsessive-Compulsive Symptoms
   Substance-Induced Anxiety Disorder (refer to Substance-Related Disorders for substance-specific codes)
   Specify if: With Generalized Anxiety/With Panic Attacks/With Obsessive-Compulsive Symptoms/With Phobic Symptoms
   Specify if: With Onset During Intoxication/With Onset During Withdrawal
300.00 Anxiety Disorder NOS

SOMATOFORM DISORDERS

300.81 Somatization Disorder
300.81 Undifferentiated Somatoform Disorder
300.11 Conversion Disorder
   Specify type: With Motor Symptom or Deficit/With Sensory Symptom or Deficit/
   With Seizures or Convulsions/With Mixed Presentation
307.xx Pain Disorder
   .80 Associated With Psychological Factors
   .89 Associated With Both Psychological Factors and a General Medical Condition
   Specify if: Acute/Chronic

300.7 Hypochondriasis
   Specify if: With Poor Insight
300.7 Body Dysmorphic Disorder
300.81 Somatoform Disorder NOS

FACTITIOUS DISORDERS

300.xx Factitious Disorder
   .16 With Predominantly Psychological Signs and Symptoms
   .19 With Predominantly Physical Signs and Symptoms
   .19 With Combined Psychological and Physical Signs and Symptoms
300.19 Factitious Disorder NOS

DISSOCIATIVE DISORDERS

300.12 Dissociative Amnesia
300.13 Dissociative Fugue
300.14 Dissociative Identity Disorder
300.6 Depersonalization Disorder
300.15 Dissociative Disorder NOS

SEXUAL AND GENDER IDENTITY DISORDERS

SEXUAL DYSFUNCTIONS
The following specifiers apply to all primary Sexual Dysfunctions:
   Lifelong Type/Acquired Type
   Generalized Type/Situational Type
   Due to Psychological Factors/Due to Combined Factors

FOR FIRST-LINE THERAPY IN DEPRESSION

CHOOSE ZOLOFT® (sertraline HCI)
Please see last pages for full prescribing information
Sexual Desire Disorders

302.71 Hypoactive Sexual Desire Disorder
302.79 Sexual Aversion Disorder

Sexual Arousal Disorders

302.72 Female Sexual Arousal Disorder
302.72 Male Erectile Disorder

Orgasmic Disorders

302.73 Female Orgasmic Disorder
302.74 Male Orgasmic Disorder
302.75 Premature Ejaculation

Sexual Pain Disorders

302.76 Dyspareunia (Not Due to a General Medical Condition)
306.51 Vaginismus (Not Due to a General Medical Condition)

Sexual Dysfunction Due to a General Medical Condition

625.8 Female Hypoactive Sexual Desire Disorder Due to ... [Indicate the General Medical Condition]
608.89 Male Hypoactive Sexual Desire Disorder Due to ... [Indicate the General Medical Condition]
607.84 Male Erectile Disorder Due to ... [Indicate the General Medical Condition]
625.0 Female Dyspareunia Due to ... [Indicate the General Medical Condition]
608.89 Male Dyspareunia Due to ... [Indicate the General Medical Condition]
625.8 Other Female Sexual Dysfunction Due to ... [Indicate the General Medical Condition]
608.89 Other Male Sexual Dysfunction Due to ... [Indicate the General Medical Condition]

Substance-induced Sexual Dysfunction
(refer to Substance-Related Disorders for substance-specific codes)

Specify if: With Impaired Desire/With
Impaired Arousal/With Impaired Orgasm/With Sexual Pain

Specify if: With Onset During Intoxication

302.70 Sexual Dysfunction NOS

Paraphilias

302.4 Exhibitionism
302.81 Fetishism
302.89 Frotteurism
302.2 Pedophilia

Specify if: Sexually Attracted to Males/Sexually Attracted to Females/
Sexually Attracted to Both

Specify if: Limited to Incest
Specify type: Exclusive Type/Nonexclusive Type

302.83 Sexual Masochism
302.84 Sexual Sadism
302.3 Transvestic Fetishism

Specify if: With Gender Dysphoria

302.82 Voyeurism
302.9 Paraphilia NOS

Gender Identity Disorders

302.xx Gender Identity Disorder

.6 in Children
.85 in Adolescents or Adults

Specify if: Sexually Attracted to Males/Sexually Attracted to Females/
Sexually Attracted to Both/
Sexually Attracted to Neither

302.6 Gender Identity Disorder NOS
302.9 Sexual Disorder NOS
EATING DISORDERS

307.1 Anorexia Nervosa
   Specify type: Restricting Type; Binge-Eating/Purging Type
307.51 Bulimia Nervosa
   Specify type: Purging Type/Nonpurging Type
307.50 Eating Disorder NOS

SLEEP DISORDERS

PRIMARY SLEEP DISORDERS

Dyssomnias

307.42 Primary Insomnia
307.44 Primary Hypersomnia
   Specify if: Recurrent
347 Narcolepsy
780.59 Breathing-Related Sleep Disorder
307.45 Circadian Rhythm Sleep Disorder
   Specify type: Delayed Sleep Phase Type/Jet Lag Type/Shift Work Type/ Unspecified Type
307.47 Dyssomnia NOS

Parasomnias

307.47 Nightmare Disorder
307.46 Sleep Terror Disorder
307.46 Sleepwalking Disorder
307.47 Parasomnia NOS

SLEEP DISORDERS RELATED TO ANOTHER MENTAL DISORDER

307.42 Insomnia Related to ... [Indicate the Axis I or Axis II Disorder]
307.44 Hypersomnia Related to ... [Indicate the Axis I or Axis II Disorder]

OTHER SLEEP DISORDERS

780.xx Sleep Disorder Due to ... [Indicate the General Medical Condition]
   .52 Insomnia Type
   .54 Hypersomnia Type
   .59 Parasomnia Type
   .59 Mixed Type
   Substance-Induced Sleep Disorder (refer to Substance-Related Disorders for substance-specific codes)
   Specify type: Insomnia Type/Hypersomnia Type/Parasomnia Type/Mixed Type
   Specify if: With Onset During Intoxication/With Onset During Withdrawal

IMPULSE-CONTROL DISORDERS NOT ELSEWHERE CLASSIFIED

312.34 Intermittent Explosive Disorder
312.32 Kleptomania
312.33 Pyromania
312.31 Pathological Gambling
312.39 Trichotillomania
312.30 Impulse-Control Disorder NOS

ADJUSTMENT DISORDERS

309.xx Adjustment Disorder
   .0 With Depressed Mood
   .24 With Anxiety
   .28 With Mixed Anxiety and Depressed Mood
   .3 With Disturbance of Conduct
   .4 With Mixed Disturbance of Emotions and Conduct
   .9 Unspecified
   Specify if: Acute/Chronic

CHOOSE ZOLOFT® (sertraline HCl)

FOR FIRST-LINE THERAPY IN DEPRESSION
PERSONALITY DISORDERS

Note: These are coded on Axis II.

301.0 Paranoid Personality Disorder
301.20 Schizoid Personality Disorder
301.22 Schizotypal Personality Disorder
301.7 Antisocial Personality Disorder
301.83 Borderline Personality Disorder
301.50 Histrionic Personality Disorder
301.81 Narcissistic Personality Disorder
301.82 Avoidant Personality Disorder
301.6 Dependent Personality Disorder
301.4 Obsessive-Compulsive Personality Disorder
301.9 Personality Disorder NOS

OTHER CONDITIONS THAT MAY BE A FOCUS OF CLINICAL ATTENTION

PSYCHOLOGICAL FACTORS AFFECTING MEDICAL CONDITION

316 ... [Specified Psychological Factor] Affecting ...
[Indicate the General Medical Condition]
Choose name based on nature of factors:
Mental Disorder Affecting Medical Condition
Psychological Symptoms Affecting Medical Condition
Personality Traits or Coping Style Affecting Medical Condition
Maladaptive Health Behaviors Affecting Medical Condition
Stress-Related Physiological Response Affecting Medical Condition
Other or Unspecified Psychological Factors Affecting Medical Condition

MEDICATION-INDUCED MOVEMENT DISORDERS

332.1 Neuroleptic-Induced Parkinsonism
333.92 Neuroleptic Malignant Syndrome
333.7 Neuroleptic-Induced Acute Dystonia
333.99 Neuroleptic-Induced Acute Akathisia
333.82 Neuroleptic-Induced Tardive Dyskinesia
333.1 Medication-Induced Postural Tremor
333.90 Medication-Induced Movement Disorder NOS

OTHER MEDICATION-INDUCED DISORDER

995.2 Adverse Effects of Medication NOS

RELATIONAL PROBLEMS

V61.9 Relational Problem Related to a Mental Disorder or General Medical Condition
V61.20 Parent-Child Relational Problem
V61.1 Partner Relational Problem
V61.8 Sibling Relational Problem
V62.81 Relational Problem NOS

PROBLEMS RELATED TO ABUSE OR NEGLECT

V61.21 Physical Abuse of Child (code 995.5 if focus of attention is on victim)
V61.21 Sexual Abuse of Child (code 995.5 if focus of attention is on victim)
V61.21 Neglect of Child (code 995.5 if focus of attention is on victim)
V61.1 Physical Abuse of Adult (code 995.81 if focus of attention is on victim)
V61.1 Sexual Abuse of Adult (code 995.81 if focus of attention is on victim)

CHOOSE ZOLOFT* (sertraline HCl)

FOR FIRST-LINE THERAPY IN DEPRESSION
Zoloft®

(sertaline hydrochloride)

Tablets

DESCRIPTION

Zoloft® (sertraline hydrochloride) is an antidepressant for oral administration. It is chemically unrelated to tricyclic, tetracyclic, or other available antidepressant agents. It has a molecular weight of 342.7. Sertaline hydrochloride has the following chemical name: (1S-cis)-1-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenemethanamine hydrochloride. The empirical formula C_{18}H_{21}ClN•HCl is represented by the following structural formula:

```
forces
```

Sertaline hydrochloride is a white crystalline powder that is slightly soluble in water and isopropyl alcohol, and sparingly soluble in ethanol.

Zoloft® is supplied for oral administration as scored tablets containing sertaline hydrochloride equivalent to 50 and 100 mg of sertaline and the following inactive ingredients: dibasic calcium phosphate dibehylate, FD&C Blue #2 aluminum lake (in 50 mg tablet), hydroxypropyl cellulose, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyethylene wax, sodium starch glycolate, synthetic yellow iron oxide (in 100 mg tablet), and titanium dioxide.

CLINICAL PHARMACOLOGY

Pharmacodynamics

The mechanisms of action of sertaline is presumed to be linked to its inhibition of CNS neuronal uptake of serotonin (5HT). Studies at clinically relevant doses in man have demonstrated that sertaline blocks the uptake of serotonin into human platelets. In vivo studies in animals also suggested that sertaline is a potent and selective inhibitor of neuronal serotonin uptake and has only very weak effects on nonserotonergic and dopamine neuronal uptake. In vivo studies have shown that sertaline has no significant affinity for adrenergic (alpha, alpha, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1, 5HT2, 5HT3, 5HT4), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of sertaline was found in animals to desensitize brain nonserotonergic receptors as has been observed with other clinically effective antidepressants. Sertaline does not exhibit monoamine oxidase.

Pharmacokinetics

Systemic availability — In man, following oral once-daily dosing over the range of 50 to 200 mg for 14 days, mean plasma concentration (Cmax) of sertaline occurred between 4.5 to 4.8 hours post dosing. The average terminal elimination half-life of plasma sertaline is about 22 hours. Based on this pharmacokinetic parameter, steady-state sertaline plasma levels should be achieved after approximately one week of once-daily dosing. Linear dose-proportional pharmacokinetics were demonstrated in a single dose study in which the Cmax and area under the plasma concentration time curve (AUC) of sertaline were proportional to dose over a range of 50 to 300 mg. Consistent with the terminal elimination half-life, there is an approximately two-fold accumulation, compared to a single dose, of sertaline with repeated dosing over a range of 50 to 200 mg dose range. The single dose bioavailability of sertaline tablets is approximately equal to that equivalent dose of solution.

The effects of food on the bioavailability of sertaline were studied in subjects administered a single dose with and without food. FUC was slightly increased when drug was administered with food but the Cmax was 25% greater, while the time to reach peak plasma concentration decreased from 8 hours post-dosing to 5.5 hours.

Metabolism — Sertaline undergoes extensive first pass metabolism. The principal initial pathway of metabolism for sertaline is N-demethylation. N-demethylation has a plasma terminal elimination half-life of 62 to 104 days. Both in vitro biochemical and in vivo pharmacological testing has shown N-desmethyl sertaline to be substantially less active than sertaline. Both sertaline and N-desmethyl sertaline undergo oxidative deamination and subsequent reduction, hydroxylation, and glucuronide conjugation. In a study of radiolabeled sertaline metabolites in healthy male subjects, sertaline accounted for less than 5% of the plasma radioactivity. About 40-45% of the administered radioactivity excreted in urine. Unchanged sertaline was not detectable in the urine. In the same study, about 40-45% of the administered radioactivity was accounted for in feces, including 12-14% unchanged sertaline. Desmethylseraline exhibits time-related, dose dependent increases in AUC (0-24 h), Cmax and AUC (t > 24 h) with a half-life approximately 20-40% greater than that of sertaline.

Desmethylseraline exhibits time-related, dose dependent increases in AUC (0-24 h), Cmax and AUC (t > 24 h) with a half-life approximately 20-40% greater than that of sertaline.

>300.9 Unspecified Mental Disorder (nonpsychotic)
V71.09 No Diagnosis or Condition on Axis I
799.9 Diagnosis or Condition Deferred on Axis I
V71.09 No Diagnosis on Axis II
799.9 Diagnosis Deferred on Axis II

MULTIAXIAL SYSTEM

Axis I Clinical Disorders
Axis II Personality Disorders
Axis III General Medical Conditions
Axis IV Psychosocial and Environmental Problems
Axis V Global Assessment of Functioning

ADDITIONAL CONDITIONS THAT MAY BE A FOCUS OF CLINICAL ATTENTION

V15.81 Noncompliance With Treatment
V65.2 Malingering
V71.01 Adult Antisocial Behavior
V71.02 Child or Adolescent Antisocial Behavior
V62.89 Borderline Intellectual Functioning

Note: This is coded on Axis II.

780.9 Age-Related Cognitive Decline
V62.82 Bereavement

V6.2 Academic Problem

313.82 Identity Problem

V62.89 Religious or Spiritual Problem

V62.4 Acculturation Problem

V62.89 Phase of Life Problem

Additional Codes

300.9 Unspecified Mental Disorder (nonpsychotic)
V71.09 No Diagnosis or Condition on Axis I
799.9 Diagnosis or Condition Deferred on Axis I
V71.09 No Diagnosis on Axis II
799.9 Diagnosis Deferred on Axis II

FOR FIRST-LINE THERAPY IN DEPRESSION

CHOOSE ZOLOFT® (sertraline HCl)

Please see last pages for full prescribing information.
Global Assessment of Functioning (GAF) Scale

Consider psychological, social, and occupational functioning on a hypothetical continuum of mental health–illness. Do not include impairment in functioning due to physical (or environmental) limitations.

**Code** (Note: Use intermediate codes when appropriate, e.g., 45, 68, 72.)

100 Superior functioning in a wide range of activities, life's problems never seem to get out of hand, is sought out by others because of his or her many positive qualities. No symptoms.

91 Absent or minimal symptoms (e.g., mild anxiety before an exam), good functioning in all areas, interested and involved in a wide range of activities, socially effective, generally satisfied with life, no more than everyday problems or concerns (e.g., an occasional argument with family members).

80 If symptoms are present, they are transient and expectable reactions to psychosocial stressors (e.g., difficulty concentrating after family argument), no more than slight impairment in social, occupational, or school functioning (e.g., temporarily falling behind in schoolwork).

71 Some mild symptoms (e.g., depressed mood and mild insomnia) OR some difficulty in social, occupational, or school functioning (e.g., occasional truancy, or theft within the household), but generally functioning pretty well, has some meaningful interpersonal relationships.

60 Moderate symptoms (e.g., flat affect and circumstantial speech, occasional panic attacks) OR moderate difficulty in social, occupational, or school functioning (e.g., few friends, conflicts with peers or co-workers).

50 Serious symptoms (e.g., suicidal ideation, severe obsessional rituals, frequent shoplifting) OR any serious impairment in social, occupational, or school functioning (e.g., no friends, unable to keep a job).

40 Some impairment in reality testing or communication (e.g., speech is at times illogical, obscure, or irrelevant) OR major impairment in several areas, such as work or school, family relations, judgment, thinking, or mood (e.g., depressed man avoids friends, neglects family, and is unable to work; child frequently beats up younger children, is defiant at home, and is failing at school).

30 Behavior is considerably influenced by delusions or hallucinations OR serious impairment in communication or judgment (e.g., sometimes incoherent, acts grossly inappropriately, suicidal preoccupation) OR inability to function in almost all areas (e.g., stays in bed all day; no job, home, or friends).

20 Some danger of hurting self or others (e.g., suicide attempts without clear expectation of death; frequently violent; manic excitement) OR occasionally fails to maintain minimal personal hygiene (e.g., smears feces) OR gross impairment in communication (e.g., largely incoherent or mute).

10 Persistent danger of severely hurting self or others (e.g., recurrent violence) OR persistent inability to maintain minimal personal hygiene OR serious suicidal act with clear expectation of death.

0 Inadequate information.